Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 13/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 5/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3023059 | 0.85 | FFAR1 (0.51) | PPARDACHEPPARAFFAR1 | |
| SCHEMBL16077453 | 0.80 | PPARD (0.53) | PPARDHSD17B1PPARACYP11B1CYP11B2 | |
| SCHEMBL13284781 | 0.80 | PPARD (0.53) | PPARDHSD17B1PPARACYP11B1CYP11B2 | |
| SCHEMBL820900 | 0.78 | HSD17B1 (0.61) | PPARDHSD17B1PPARAFFAR1 | |
| SCHEMBL12035621 | 0.78 | HSD17B1 (0.61) | PPARDHSD17B1PPARAFFAR1 | |
| SCHEMBL30515129 | 0.78 | HSD17B1 (0.61) | PPARDHSD17B1PPARAFFAR1 | |
| SCHEMBL2464209 | 0.78 | HSD17B1 (0.61) | PPARDHSD17B1PPARAFFAR1 | |
| SCHEMBL3962243 | 0.77 | PPARD (0.48) | PPARDHSD17B1PPARACYP11B1CYP11B2 | |
| SCHEMBL12799026 | 0.77 | PPARD (0.49) | PPARDHSD17B1PPARAFFAR1 | |
| SCHEMBL12035617 | 0.76 | PPARD (0.60) | PPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7906653-B2 | Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation | BAYER HEALTHCARE LLC (US) | 2011-03-15 | — | — | US | disclosed |
| US-7906653-B2 | Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation | BAYER HEALTHCARE LLC (US) | 2011-03-15 | — | — | US | disclosed |
| EP-1578715-B1 | INDANE ACETIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS, INTERMEDIATES, AND METHOD OF PREPARATION | BAYER PHARMACEUTICALS CORP (US) | 2011-03-02 | — | — | EP | disclosed |
| US-20100204472-A1 | Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation | CANTIN LOUIS-DAVID | 2010-08-12 | — | — | US | disclosed |
| US-20100204472-A1 | Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation | CANTIN LOUIS-DAVID | 2010-08-12 | — | — | US | disclosed |
| US-7714004-B2 | Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation | BAYER PHARMACEUTICALS CORPORATION (US) | 2010-05-11 | — | — | US | disclosed |
| US-7714004-B2 | Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation | BAYER PHARMACEUTICALS CORPORATION (US) | 2010-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204472-A1 | Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation | INSR, ACACA, IAPP | PPARD 978/4885ACHE 196/4885HSD17B1 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.